34 results
8-K
EX-99.1
VIR
Vir Biotechnology Inc
2 May 24
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
4:09pm
plans to host a virtual R&D day in late November.
Effective May 3, 2024, Sung Lee, Executive Vice President and Chief Financial Officer will be stepping … of sotrovimab.
Research and Development Expenses (R&D): R&D expenses for the first quarter of 2024 were $100.1 million, which included $13.6 million of non
8-K
EX-99.1
VIR
Vir Biotechnology Inc
22 Feb 24
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4:12pm
creation, which include:
◦Closing R&D facilities in St. Louis, Missouri and Portland, Oregon in 2024. Research activities will continue at the Company’s … of sotrovimab.
Research and Development Expenses (R&D): R&D expenses for the fourth quarter of 2023 were $111.9 million, which included severance
8-K
EX-99.1
VIR
Vir Biotechnology Inc
6 Apr 20
Entry into a Material Definitive Agreement
8:02am
coronavirus vaccines.
Dr. Hal Barron, Chief Scientific Officer and President R&D, GSK, said: “Vir’s unique antibody platform has precedented success … in identifying and developing antibodies as treatments for multiple pathogens, and it is highly complementary with our R&D approach to focus on the science
8-K
EX-99.1
VIR
Vir Biotechnology Inc
4 May 23
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:16pm
royalties owed based on the sales of sotrovimab under the Company’s collaboration with GSK.
Research and Development Expenses (R&D): R&D expenses … from income taxes was primarily due to a pre-tax loss and our ability to carry-back the R&D credit to 2022.
Net (Loss) Income: Net loss attributable
8-K
EX-99.1
VIR
Vir Biotechnology Inc
2 Nov 23
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
4:09pm
on the sales of sotrovimab.
Research and Development Expenses (R&D): R&D expenses for the third quarter of 2023 were $148.3 million, which included $15.8 … -back the R&D credit to 2022.
Net (Loss) Income: Net loss attributable to Vir for the third quarter of 2023 was $(163.4) million, or $(1.22) per share
DEFA14A
inmgqkb0jd w6s5ivcr
14 May 24
Additional proxy soliciting materials
4:05pm
8-K
EX-99.1
90jd27a3b3ef37vk
5 May 22
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results
12:00am
8-K
EX-99.1
55ng7
3 Aug 23
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:14pm
8-K
EX-99.1
n73 tluf9iscb
9 Aug 22
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
12:00am
8-K
totf689
6 Jul 20
Our mission is to create a world without infectious disease
6:32am
8-K
EX-99.1
or3o 6cvnat0pf
13 Apr 21
Other Events
4:06pm
8-K
EX-99.1
cyt nlseq7sma23
19 Feb 21
GSK and Vir Biotechnology Expand Coronavirus Collaboration to Advance New Therapeutics for Influenza and Other Respiratory Viruses
5:03pm
8-K
EX-99.2
gco lhsh3
27 May 21
GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives
4:55pm
8-K
EX-99.1
7jbdbdonjs yiuue
11 Aug 20
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2020 Financial Results
4:05pm
8-K
EX-99.2
xmkqpox6m3oasxo7p9x
24 Feb 22
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
4:27pm
8-K
EX-99.2
4k6vkm 4lhuw
28 Jan 21
Other Events
4:05pm
8-K
EX-99.1
fost8wj4c0jyzuoks3nu
27 May 21
GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives
4:55pm
8-K
EX-99.1
tppk6vv7tyli
24 Feb 22
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
4:27pm